The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of trilaciclib combined with standard treatment project
as a neoadjuvant treatment for triple negative breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University